AmideBio, LLC, founded with a mission to innovate in the biotechnology sector, focuses on the development, production, and commercialization of peptide research reagents and clinical products. The company leverages its in-silico design and proprietary peptide synthesis capabilities to create a pipeline of unique peptide drug candidates targeting metabolic diseases. AmideBio serves the research and development, clinical, and therapeutic markets with a range of custom synthesis services and a comprehensive peptide catalog.
Notable affiliated individuals and investors include experts in biotechnology and pharmaceuticals who contribute to the company's strategic direction. AmideBio has achieved significant milestones in peptide drug discovery, positioning itself as a leader in the biotech industry. Its impact is evident in the advancement of peptide-based therapies and the support it provides to researchers and clinicians in developing innovative treatments for metabolic diseases.
